• Introduction:

    Katia Khoury, MD, is Assistant Professor of Medicine. She is a clinician-educator in the Division of Hematology and Oncology who works in outpatient breast clinics as well as inpatient services at the University of Alabama at Birmingham. Dr. Khoury earned her M.D. from the American University of Beirut (AUB) in 2012, followed by two years of post-doctoral research in the Division of Hematology and Oncology at AUB. She completed her Internal Medicine residency at Case Western Reserve University/ University Hospitals Cleveland Medical Center in 2017; and she subsequently trained as a Hematology and Oncology fellow at MedStar Georgetown University Hospital. She joined the faculty at UAB in 2020.

    Clinical & Research Interests:

    She has a clinical and research interest in breast oncology, with a focus on breast cancer management, hereditary breast cancer syndromes, health disparities, and practice areas with limited resources.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2020 Prevalence of Phosphatidylinositol-3-Kinase (PI3K) Pathway Alterations and Co-alteration of Other Molecular Markers in Breast Cancer.Frontiers in Oncology.  10:1475. 2020
    2018 Randomized trial of proactive rapid genetic counseling versus usual care for newly diagnosed breast cancer patients.Breast Cancer Research and Treatment.  170:517-524. 2018
    2018 Risk and Prevention for Highly Penetrant GenesCurrent Breast Cancer Reports.  10. 2018
    2017 Practice and Impact of Multidisciplinary Tumor Boards on Patient Management: A Prospective Study.Journal of Global Oncology.  3:242-249. 2017
    2015 Global Practice and Efficiency of Multidisciplinary Tumor Boards: Results of an American Society of Clinical Oncology International Survey.Journal of Global Oncology.  1:57-64. 2015
    2015 BRCA1 and BRCA2 mutations in ethnic Lebanese Arab women with high hereditary risk breast cancer. 2015
    2014 Enhancing cancer care in areas of limited resources: our next steps.Future Oncology.  10:1953-1965. 2014
    2014 Small Cell Lung Cancer with Metastasis to the Breast: A Case Report and Review of the LiteratureCancer Biology and Research.  2. 2014
    2014 Outcome of Breast Cancer Patients Treated outside of Clinical Trials.Journal of Cancer.  5:491-498. 2014
    2014 Tumor boards: optimizing the structure and improving efficiency of multidisciplinary management of patients with cancer worldwide.American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting.  e461-e466. 2014
    2013 Re: Tumor boards and the quality of cancer care. 2013
    2013 Epidemiology and prognosis of breast cancer in young women.Journal of Thoracic Disease2013
    2013 Cancer in Lebanon: Incidence, History, and Developments of TherapyLe Journal medical libanais. The Lebanese medical journal.  61. 2013

    Principal Investigator On

    Investigator On

  • A Phase II Trial of HKI-272 (Neratinib) and Capecitabine for Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer and Brain Metastases  awarded by Dana-Farber Cancer Institute
  • Private Grant  awarded by SAPERE BIO
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd.
  • Private Grant  awarded by Pfizer Pharmaceuticals
  • Private Grant  awarded by ZYMEWORKS BIOPHARMACEUTICALS
  • Private Grant  awarded by MERCK SHARP & DOHME CORP
  • Private Grant  awarded by CYTOMX THERAPEUTICS
  • Private Grant  awarded by STRATA ONCOLOGY
  • Private Grant  awarded by CELCUITY
  • Private Grant  awarded by CELCUITY
  • Private Grant  awarded by GREENWICH LIFESCIENCES, INC.
  • Private Grant  awarded by Genentech
  • UAB 1846: A Phase 2 Study of Olaparib Monotherapy in Metastatic Breast Cancer Patients with Germline or Somatic Mutations in DNA Repair Genes  awarded by Johns Hopkins University
  • XUAB 2167 - A Phase II Circulating Tumor DNA Enriched, Gnomically Directed Post-Neoadjuvant Trial for Patients with Residual Triple Negative Breast Cancer (PERSEVERE): HCRN BRE18-334  awarded by HOOSIER CANCER RESEARCH NETWORK
  • XUAB2107-A Multi-institutional Phase II Study to Evaluate Efficacy and Safety of TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative Patients with PD-L1+ Metastatic Triple Negative Breast Cancer (TARA)  awarded by HOOSIER CANCER RESEARCH NETWORK
  • XUAB2147-Phase I/II Study of Stereotactic Radiosurgery with Concurrent Administration of DNA Damage Response (DDR) Inhibitor (Olaparib) Followed by Adjuvant Combination of Durvalumab (MEDI4736) and Physician’s Choice Systemic Therapy in Subjects with Breast Cancer Brain Metastases  awarded by HOOSIER CANCER RESEARCH NETWORK
  • [18F] Fluoroestradiol (FES) PET as a Predictive Measure for Endocrine Therapy in Women with Newly Diagnosed Metastatic Breast Cancer (R20-146)  awarded by ECOG-ACRIN CANCER RESEARCH GROUP
  • Education And Training

  • American University of Beirut, Postdoctoral Research
  • University Hospitals Case Medical Center, Residency
  • MedStar Georgetown University Hospital, Postdoctoral Fellowship
  • Doctor of Medicine, American University of Beirut 2012
  • Bachelor of Science or Mathematics in Biology, American University of Beirut 2008
  • Full Name

  • Katia Khoury